Skip to main content
Caplight Logo









Syntis Bio, Inc.

Syntis Bio, Inc.

Private
Boston, MassachusettsHealthcare & Life Scienceshttps://syntis.bio/

Last Round

Series A

Jul 1, 2025

Est. Valuation

$67M

Total Funding Raised

$53.5M

Company Overview

Syntis Bio, Inc. is a clinical-stage biopharmaceutical company developing oral therapies that harness the small intestine's biology for conditions like obesity, diabetes, and rare diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Government Contracts

AI Layer

Non-AI

Keywords

biopharmaceuticaloral drug deliveryoral biologicsgastrointestinal targetinggut-targeted therapyenzyme replacement therapyGI drug deliverybiomaterialsmetabolic diseasepill-based therapydrug discoveryobesity treatmentpolymer coatingrare metabolic disordersclinical development

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Syntis Bio, Inc. Comparables

Compare Syntis Bio, Inc. with similar companies based on industry and business-model similarity.

Syntis Bio, Inc. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Glyscend Therapeutics
86%
Aphaia Pharma
76%
Biolexis Therapeutics, Inc.
75%

Syntis Bio, Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AJul 1, 2025
GrantJul 1, 2025

Key People

Founding team and executive leadership

Phil Gardella

Chief Financial Officer

Executive Team

Christo Shalish

Chief Business Officer

Executive Team

Syntis Bio, Inc. Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 11, 2026

    David Rosenbaum appointed as Chief Development Officer.

  • Mar 3, 2026

    Christo Shalish appointed as the new Chief Business Officer.

Recent news

Latest coverage and updates

  • is_developingSep 23, 2026

    Syntis Bio, Inc. will develop SYNT-101 on Jul 1st '27.

  • is_developingSep 2, 2026

    Syntis Bio, Inc. is developing pill-based therapies.

Syntis Bio, Inc. Filings

Explore SEC and related filing metadata, where available.

Syntis Bio, Inc. filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Firmographic Details

HeadquartersBoston, Massachusetts
Employee Range23
Year Founded2022
Last FundingJul 1, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?